Dracen Announces Clinical Collaboration with Merck

Dracen will develop sirpiglenastat (DRP-104) in combination with KEYTRUDA® in selected patients with Non-Small Cell Lung Cancer(PRWeb March 08, 2021)Read the full story at https://www.prweb.com/releases/dracen_announces_clinical_collaboration_with_merck/prweb17775654.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news